Author:
Alghandour Reham,Ebrahim Mohamed A.,Elshal Ahmed M.,Ghobrial Fady,Elzaafarany Maha,ELbaiomy Mohamed A.
Reference36 articles.
1. Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations;Dellis;Cancer treatment reviews,2019
2. Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis;Tong;Cancer letters,2017
3. James, N.D., M.R. Sydes, N.W. Clarke, M.D. Mason, D.P. Dearnaley, M.R. Spears, et al., Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 2016. 387(10024): p. 1163–1177.
4. Kyriakopoulos, C.E., Y.-H. Chen, M.A. Carducci, G. Liu, D.F. Jarrard, N.M. Hahn, et al., Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.2018. 36(11): p. 1080–1087.
5. Fizazi, K., N. Tran, L. Fein, N. Matsubara, A. Rodriguez-Antolin, B.Y. Alekseev, et al., Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.2019. 20(5): p. 686–700.
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献